InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard Neuroprotection System

Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke

TEL AVIV, Israel and MIAMI, Dec. 20, 2023 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the issuance of U.S. Patent No. 11,844,893, titled, “Shunts with Blood Flow Indicators.”

The patent covers key aspects of the company’s SwitchGuard Neuroprotection System (NPS) along with future features in development that are expected to enable the treating physician to visualize flow through the system. The SwitchGuard NPS is designed to allow the physician to reverse blood flow to the brain during a carotid artery stenting procedure, including Transcarotid Artery Revascularization (TCAR) or other neurovascular procedures. The SwitchGuard NPS is designed to prevent embolic debris generated during the procedure from traveling to the brain, passing the blood through the filter housed within the SwitchGuard before returning it to the patient, to minimize blood loss during the procedure.

In October 2023, the Centers for Medicare and Medicaid Services (CMS) expanded coverage for carotid artery stenting (CAS) and TCAR to include both asymptomatic and standard risk patients at either high- or standard- risk for carotid endarterectomy (surgery). The broader availability of these less invasive options should better enable physicians to tailor treatment plans to the needs of individual patients.

Marvin Slosman, Chief Executive Officer of InspireMD, stated, “The issuance of this patent demonstrates our continued priority to develop and build on our robust intellectual property to support our innovations, while expanding our product portfolio for optimal patient outcomes in the treatment of carotid artery disease with the utmost safety in mind. This coupled with our CGuard Prime Carotid Stent System should provide clinicians with innovation and safety during carotid revascularization procedures and minimize the risk of stroke.”

InspireMD expects to submit an Investigational Device Exemption (IDE) to the FDA in 2024, which, if approved, would allow the company to initiate a clinical trial to support the clearance of the SwitchGuard NPS coupled with CGuard Prime.

About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR.